(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 December 2022 (08.12.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/254377 A1

(51) International Patent Classification:
A61K 47/68 (2017.01) *A61P 35/00* (2006.01)
A61K 31/454 (2006.01)

(21) International Application Number:
PCT/IB2022/055168

(22) International Filing Date:
02 June 2022 (02.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/202,272 03 June 2021 (03.06.2021) US
63/282,588 23 November 2021 (23.11.2021) US

(71) Applicant: **ORUM THERAPEUTICS, INC.** [KR/KR]; 2F, 281-25, Munji-ro, Yuseong-gu, Daejeon, 34050 (KR).

(72) Inventors: **FISHKIN, Nathan**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US). **PARK, Peter U.**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US). **BAI, Chen**; Orum Therapeutics, Ipsen Innovation Center/Biolabs, 650 East Kendall St., Cambridge, Massachusetts 02142 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: NEODEGRADER-ANTI-CD33 ANTIBODY CONJUGATES

(57) Abstract: The present disclosure provides neoDegraders conjugated to anti-CD33 antibodies. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.

WO 2022/254377 A1